Palladia for Dogs - (toceranib phosphate) 10 mg (1 Tablet) - [Prevents Tissue Inflammation]

Palladia^® (toceranib phosphate) is an FDA-approved antiproliferative and antiangiogenic agent used for the treatment of Patnaik grade II or III cutaneous mast cell tumors in dogs, with or without regional lymph node involvement. This targeted therapy uses toceranib phosphate to inhibit tumor growth and can serve as a non-traditional alternative to chemotherapy for various other types of canine tumors, including thyroid carcinomas and melanomas.

Palladia is available in 10 mg, 15 mg, and 50 mg strengths, making it easier to tailor the dose to your dog’s weight and condition. Each strength is available individually or in bottles of 30 tablets.

Key Features

• Treats Patnaik grade II or III recurrent cutaneous mast cell tumors in dogs
• Can be used as an alternative to traditional chemotherapy for certain other tumor types
• Available in three dosage strengths: 10 mg, 15 mg, and 50 mg
• Sold by individual tablet or in bottles of 30 for flexible treatment planning

How It Works

• Functions as an antiproliferative and antiangiogenic agent
• Helps reduce inflammation associated with malignant tumors
• Inhibits tyrosine kinase—disrupting both tumor cell activity and its supporting blood supply

Conditions Treated

• Primary indication: Mast cell tumors in dogs
• May also be used (off-label) to manage other cancers, including:
• Squamous Cell Carcinoma
• Metastatic Osteosarcoma
• Malignant Melanoma
• Anal Sac Adenocarcinoma
• Vaccine-Associated Fibrosarcoma
• Transitional Cell Carcinoma
• Thyroid Carcinoma

Active Ingredient

Toceranib

Dosage & Administration

Always provide the Client Information Sheet with the prescription. The recommended starting dose of Palladia is 3.25 mg/kg (1.48 mg/lb) of body weight, administered orally every other day.

If adverse reactions occur, your veterinarian may reduce the dose by 0.5 mg/kg, to a minimum of 2.2 mg/kg (1.0 mg/lb), or pause treatment for up to two weeks. Dose adjustments should be based on veterinary assessments, typically conducted weekly for the first six weeks, and approximately every six weeks thereafter.

Palladia may be given with or without food. Do not split or crush tablets.

Quick Tips

• Consult your veterinarian to determine the correct starting dose for your dog.
• Dose is based on body weight and may require adjustment over time.
• Administer Palladia every other day, as directed.
• Tablet reductions or dose interruptions may be used to manage side effects.
• Veterinary follow-ups are essential to monitor your pet’s response and safety.

Dosage Table

The dosage chart below outlines tablet combinations based on your dog’s weight. Your veterinarian will select the appropriate strength(s) to reach the target dose.

Note: Full dosage table available on product label. The below is for general guidance only.

View Palladia product label.

Storage Directions

Store Palladia at controlled room temperature between 20°C to 25°C (68°F to 77°F). Keep out of reach of children and pets.

Contraindications

Do not use in dogs that are pregnant, lactating, or intended for breeding.

Warnings

Palladia may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. If these signs occur, discontinue use until clinical symptoms and laboratory values return to normal. To maintain vascular stability, wait at least three days after stopping treatment before performing surgery.

Human Warnings

NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN.
Children should avoid contact with treated dogs, especially their feces, urine, or vomit. Adults should wear gloves and wash hands after handling the medication or waste. Avoid direct contact with broken or moistened tablets. Dispose of gloves and waste in sealed plastic bags.

If accidental eye exposure occurs, rinse thoroughly with water. In case of accidental ingestion, contact a physician immediately. Pregnant women, or those who may become pregnant, should take special care when handling Palladia, as it may interfere with blood vessel formation in the developing fetus and cause birth defects.

Potential Side Effects

In a U.S. clinical study of 151 dogs, the most commonly reported side effects included:

• Diarrhea
• Vomiting
• Anorexia (loss of appetite)
• Lethargy
• Lameness
• Weight loss
• Bloody stool
• Dehydration
• Itching (pruritus)
• Pigmentation changes
• Dermatitis
• Musculoskeletal disorders